Get the Stockscreener App
0.973
0.18%
-0.0018
Tempest Therapeutics Inc stock is traded at $0.973, with a volume of 94,064.
It is down -0.18% in the last 24 hours and down -23.39% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
See More
Previous Close:
$0.9748
Open:
$0.98
24h Volume:
94,064
Relative Volume:
0.54
Market Cap:
$15.55M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.1567
EPS:
-6.2098
Net Cash Flow:
$-26.38M
1W Performance:
-10.73%
1M Performance:
-23.39%
6M Performance:
-32.66%
1Y Performance:
-73.56%
1-Day Range:
$0.96
$1.00
1-Week Range:
$0.95
$1.0993
52-Week Range:
$0.95
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.973 | 15.55M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et
Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo
Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
TPST Forecast — Price Target — Prediction for 2027 - TradingView
TPST: Selling Stockholders Plan to Offer 2.43 Million Shares - GuruFocus
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan
3OS0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBITDA forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST) - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBIT forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock By Investing.com - Investing.com South Africa
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock - Investing.com
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants - Stock Titan
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares By Investing.com - Investing.com South Africa
Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
TPST PE Ratio & Valuation, Is TPST Overvalued - Intellectia AI
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares - Investing.com
Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances - Stock Titan
Tempest Therapeutics, Inc. 8-K Filing – Special Meeting Results, Common Stock Issuance Approved, Company Details (June 2026) – Minichart - Minichart
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempest Therapeutics Inc (TPST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Director at Tempest Therapeutics (TPST) receives 25,000 stock options grant - Stock Titan
[Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Tempest Therapeutics (TPST) Climbs 2.8% as Stock Approaches Critical $1.34 Resistance LevelLow Risk Entry Stocks - newsline.com
Tempest Therapeutics Inc (TPST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tempest Therapeutics Inc (TPST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tempest Therapeutics | S-8 POS: S-8 POS - Moomoo
Tempest Therapeutics (TPST) Edges Higher as Stock Tests Resistance Near $1.34EMA Signal - newsline.com
Director Richey William Drake reports 2,000 TPST shares on Form 3 - Stock Titan
Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike - Stock Titan
Warrant share approvals on ballot at Tempest Therapeutics (NASDAQ: TPST) - Stock Titan
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com India
Tempest Therapeutics Announces CFO Transition and Board Changes - TipRanks
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):